|
| FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Atrial Flutter |
2 Jul 09, 08:12 |
|
| PARIS, July 2 /PRNewswire/ -- - Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter - U.S Commercial Launch Planned for the Summer of 2009 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. |
| more |
|
